Kornimate/medical-research-clean huggingface dataset:
effects of social exclusion in the context of chronic embitterment

Conditions: Emotional Stress; Embitterment

Summary: this experimental, anonymous labor study aims to examine how experiences of social exclusion influence individuals in their fairness-behaviour, psychophysical reactions, and emotion regulation depending on their extent of bitterness. points given for fairness reasons, just world belief, rejection sensitivity, well-being, cognitive emotion regulation strategies, and heart rate variability (hrv) are measured and analyzed using structural equation modeling and multiple regression.

embitterment is defined as an emotional response due to an event which is subjectively perceived as unjust. nonetheless, there is little empiric evidence of unjust behaviour by others in the interpersonal context that triggers embitterment reactions. ostracism, is an act where a person is excluded from a social environment without any reasons. this experimental labor study examines how the experiences of this form of social exclusion influences individuals depending on their self-evaluated embitterment. that is, fairness-behaviour is assessed as well as changes in hearth rate variability.

Eligibility criteria:
inclusion criteria: * german language, 18 years old, no cardiovascular disease * the participation in the anonymous labor study is voluntary, participants gave consent to use the data with their participation. exclusion criteria: * none
rehabilitation of the stroke hand at home

Conditions: Stroke

Summary: the purpose of this research is to evaluate a therapy delivery system for stroke patients that provide accessible, affordable stroke care. user-friendly home therapy robots and a telerehabilitation system are combined to monitor and provide therapy that is accessible for patients in rural and underserved locations. the robotic-based home therapy intervention will produce significantly greater improvement in upper extremity motor function than usual and customary care enhanced with a (non-robotic) home therapy upper extremity rehabilitation program at the end of 8 weeks of home therapy.

the primary purpose of this proposal is to evaluate a combined clinic/home robotic-based stroke therapy delivery and monitoring system in rural and underserved locations that provides accessible, effective and affordable care for stroke survivors with residual limb impairment. the study is a prospective, single-blind, multi-site randomized controlled trial. a total of 96 patients within 6 months post-stroke will be enrolled and randomly assigned to one of two groups: robotic based home therapy or a self administered (non-robotic) home therapy program.

Eligibility criteria:
inclusion criteria: * unilateral ischemic or hemorrhagic stroke * within 6 months of admission to in-patient rehabilitation * persistent hemiparesis * proximal upper extremity voluntary activity * preserved cognitive function * difficult access to an organized stroke rehabilitation program exclusion criteria: * not independent before stroke * hemispatial neglect * significant other illnesses

Keywords: stroke rehabilitation home rehabilitation robotic therapy
pd-1 combined with intensity modulated radiation therapy in the treatment of intermediate-risk nasopharyngeal carcinoma

Conditions: Nasopharyngeal Carcinoma; T2-3N0 or T1-2N1; EBV-DNA≤4000 Copy/ml

Summary: to evaluate the safety and efficacy of pd-1 immune checkpoint inhibitor combined with intensity modulated radiation therapy in the treatment of intermediate-risk nasopharyngeal carcinoma (t2-3n0 or t1-2n1 stage and ebv-dna≤4000 copy/ml).

to evaluate the safety and efficacy of pd-1 immune checkpoint inhibitor combined with intensity modulated radiation therapy in the treatment of intermediate-risk nasopharyngeal carcinoma (t2-3n0 or t1-2n1 stage and ebv-dna≤4000 copy/ml).the primary end point is safety, the secondary end points are short-term efficacy,overall survival (os), progression-free survival (pfs),distant metastasis-free survival(dmfs),adverse effects ,quality of life and immune status assessment.

Eligibility criteria:
inclusion criteria: * newly diagnosed patients who have not received radiotherapy or chemotherapy * pathologically diagnosed as non-keratinizing nasopharyngeal carcinoma (differentiated or undifferentiated, who classification type ii or type iii). * t2-3n0 or t1-2n1 stage and ebv-dna≤4000 copy/ml (ajcc 8th version) and ebv-dna≤4000copies/ml * male or non-pregnant female * age between 18 and 65 * eastern cooperative oncology group（ecog）score of 0-1. * hemoglobin (hgb) ≥90 g/l, white blood cell (wbc) ≥4×109/l, platelet (plt) ≥100×109/l. * liver function: alanine aminotransferase (alt), aspartate aminotransferase (ast) \<2.0 times the upper limit of normal (uln); total bilirubin \<2.0×uln. * renal function: creatinine clearance rate ≥60ml/min or serum creatinine \<1.5×uln. * the patient has signed the informed consent exclusion criteria: * the pathology is keratinizing squamous cell carcinoma (who classification is type i). * patients with recurrence and distant metastasis. * patients who have undergone radiotherapy or chemotherapy. * active hepatitis b (hbv-dna≥500). * patients with autoimmune diseases. * patients with hiv infection. * at the same time suffering from other uncontrolled serious diseases. * persons with abnormal functions of the heart, brain, lungs and other important organs. * age\> 65 years. * pregnancy or breast feeding. * persons with personality or mental illness, without or with limited capacity for civil conduct
evaluation of post-vaccination anti-sars-cov-2 serological response in health care workers with a history of covid-19.

Conditions: SARS CoV 2 Infection; Vaccination Reaction

Summary: since the beginning of 2020, a major pandemic due to the new emerging coronavirus (sars-cov-2) has been spreading around the world. today, the hope to contain this pandemic lies in the development and use of vaccines directed against this virus. different strategies aim to maximize the early impact of vaccination in a context where few doses are available. in early january 2021, large-scale vaccination began in france, first for populations at risk of severe covid-19, but also for healthcare workers over 50 years of age or with an underlying pathology, and then for all voluntary healthcare workers.

the question of vaccination of patients with a history of recent or late sars-cov-2 infection has rapidly become a major issue. currently, french recommendations call for a single dose in the cohort that has been cured of covid-19 for six months. in addition, the use of anti-sars-cov2 serology may be of interest because the presence of antibodies indicates recent or past contact with sars-cov-2. however, serological testing is not included in the vaccination decision strategy. the goal of the investigators is to provide data on the immune response induced by sars-cov-2 vaccines in a real-world setting to support this choice. given the absence of recommendations concerning the realization of the anti-sars-cov-2 serology, it will be proposed to all the nursing staff of the groupe hospitalier paris saint joseph at the time of their vaccination, a serological screening. the investigators will evaluate the dynamics of antibody production against the sars-cov-2 spike protein after the first and second dose of vaccine (conventional prime-boost strategy recommended) in healthcare workers with or without a history of covid-19.

Eligibility criteria:
inclusion criteria: * health care workers of the paris saint joseph hospital group whose age ≥ 18 years * french-speaking * health care workers who have received the bnt162b2 mrna vaccine (comirnaty, pfizer/biontech). exclusion criteria: * health care workers under guardianship or curatorship * health care workers under court protection * health care workers who object to the use of their data for this research
impact of underlying renal disease and immunosuppressive regimen on ovarian reserve in renal patients

Conditions: Anti-Mullerian Hormone Deficiency; Immunosuppression; Ovarian Reserve; X-rays; Effects

Summary: aging, renal pathology (eg sle, adpkd), x-ray exposition and pharmacological treatments, especially previous strong immunosuppression, may negatively influence the ovarian reserve in childbearing age women. anti-müllerian hormone (amh) is regarded as biomarker for ovarian reserve. every female with renal disease regularly menstruating that met exclusion criteria could have participated. the aim was to assess ovarian reserve in female patients with normal menstrual cycle and kidney disease, including kidney transplant recipients.


Eligibility criteria:
inclusion criteria: * conscious written approval * autoimmunological disorder with kidneys affection/ kidney transplant recipient- regular menstrual cycles * age above 18 years old exclusion criteria: * irregular menstrual cycles * menopause * pcos * chemiotherapy or radiotherapy in the past * surgical interventions within ovaries * hypogonadotropic hypogonadism * folliculoma * age under 18 years old

Keywords: amh immunosuppression ovarian reserve x-ray effects
ultrasound guided retrolaminar versus erector spinae plane block for postoperative analgesia

Conditions: Analgesia

Summary: thoracic epidural anesthesia (tea) and paravertebral block (pvb) have been utilized to give perioperative regional anesthesia in the trunk. tea is technically troublesome in some cases, and is associated with a danger of serious complications, such as epidural hematoma, nerve injury, and hypotension. pvb has the benefit of perception of the needle position using ultrasonography. however, pvb is also additionally connected with a danger of serious complications, such as pneumothorax, hypotension, or nerve injury. newer approaches to deal with pvb have been the focal point of numerous techniques lately; these methodologies incorporate retrolaminar block (rlb) and erector spinae plane block (espb)

modified radical mastectomy is one of the commonly performed breast surgery. postoperative pain following mastectomy should be minimized, as in a number of women it may chronically persist for months in the form of post-mastectomy pain syndrome. morphine administration for acute pain after mastectomy surgery has many side effects. regional block techniques as para-vertebral block and thoracic epidural anesthesia have possible complications and technical difficulties. the new alternative regional techniques such as erector spinae plane block and retrolaminar block are clinical trials for providing a safe and easy with good hemodynamic and recovery profile with adequate perioperative analgesia for a large section of patients undergoing mastectomy operation in order to reduce opioids consumption and subsequently avoid opioid-related adverse effects. as percent of post-operative rescue analgesia is 16.7% and 60% for rlb group and espb group respectively. so, sample size is 46 patients (23 patients in each group). sample was calculated using open epi program with confidence level 95% and power 80%.

Eligibility criteria:
inclusion criteria: * patient acceptance. * 21 - 64 years of age. * american society of anesthesiologist physical status class i,ii. * body mass index 25-35 kg/m2. * female patient undergoing elective unilateral modified radical mastectomy under general anesthesia. exclusion criteria: * coagulation disorders or anticoagulant therapy. * known allergy to study drugs (bupivacaine, fentanyl) * infection at the injection site. * patients having chronic pain or on pain treatment. * advanced renal, respiratory, hepatic or cardiovascular disorders. * uncooperative patients. * duration of surgery \> 3hours. * pregnant or lactating females. * metastasis.
cvd 38000: study of responses to vaccination with typhoid and/or cholera

Conditions: Typhoid and/or Cholera Vaccination

Summary: this is an open-label, non-randomized study. the purpose of this study is to better understand how vaccines against typhoid fever and cholera affect the normal immune system and bacteria in the intestine. patients having standard-of-care endoscopies (colonoscopy and/or esophagogastroduodenoscopy (egd)) will be divided into 3 groups: group 1: vivotif typhoid vaccination and/or vaxchora cholera vaccination then endoscopy group 2: endoscopy, then vivotif typhoid vaccination and/or vaxchora cholera vaccination, then follow-up endoscopy group 3: endoscopy without vaccination. both vaccines used in this study are licensed by the food and drug administration (fda) for travelers to developing countries. volunteers will be asked to donate tissue, blood, saliva and stool samples for studying how the body responds to the typhoid and/or cholera vaccine.


Eligibility criteria:
inclusion criteria: * 1. age 18 years and older * 2. already scheduled to undergo an egd or colonoscopy for screening, surveillance, or a medically-indicated work-up at the university of maryland medical center (main campus or midtown) * 3. able to provide written informed consent prior to initiation of any study procedures * 4. healthy, as defined by considered fit to undergo outpatient elective egd/colonoscopy by the evaluating health care provider exclusion criteria: * 1. pregnancy or nursing mother * 2. known coagulopathy or bleeding disorder preventing mucosal biopsy * 3. history of crohn's disease or ulcerative colitis * 4. for subjects undergoing lower endoscopy (colonoscopy) only: surgical removal of the ileocecal valve or any part of the small or large intestine (non-complicated appendectomy will be considered eligible) * 5. allergic reaction to oral typhoid or cholera vaccine in the past * 6. immunosuppression from illness or treatment, including 1. immune-deficiency disorders such as human immunodeficiency virus (hiv) or acquired immunodeficiency syndrome (aids) 2. leukemia, lymphoma, or cancers (localized non-melanoma skin cancers which are deemed inactive should be considered eligible) * 7. receipt of any other vaccine two weeks prior to receipt of ty21a or cvd 103-hgr * 8. positive urine pregnancy test (hcg) prior to colonoscopy or vaccination
almorexant (act 078573) in adult subjects with chronic primary insomnia

Conditions: Primary Insomnia

Summary: a polysomnography study to evaluate the effect, safety and tolerability of oral administration of almorexant (act 078573) in adult subjects with primary insomnia.


Eligibility criteria:
inclusion criteria: * adult subjects (18-64 years) with a diagnosis of primary insomnia. exclusion criteria: * history of any sleep disorder, or any diagnostic and statistical manual of mental disorders, 4th edition (dsm-iv) axis i disorder other than primary insomnia. * sleep apnea, or restless legs syndrome. * daytime napping of more than 1 hour per day. * important caffeine consumption, heavy tobacco use, alcohol or drug abuse within 2 years prior to the screening visit. * unwillingness to refrain from drugs, over-the-counter or herbal medication having an effect on sleep or behavior.

Keywords: sleeplessness orexin receptor antagonist almorexant insomnia
infliximab, regulatory t cells, il2 and crohn's disease

Conditions: Crohn's Disease

Summary: crohn's disease is an inflammatory (swelling and soreness) disorder of the digestive tract. affected patients suffer from abdominal pains, diarrhea (sometimes bloody), weight loss. it is a lifelong disease with frequent flares during the course of the disease. crohn's disease is mostly treated with medications, sometimes surgery is needed. infliximab is a medication for treating severe crohn's disease. this medicine is effective by blocking special substance (tumor necrosis factor) released from certain white blood cells in the body. infliximab is given via a vessel at week 0, 2, 6 initially, then every 2 monthly for maintenance. however, some of patients with crohn's disease do not respond infliximab. currently there is no test to reveal which patients will respond to treatment. this study aims to analyze and compare particular subgroup of white cells and its products during and after infliximab treatment which may determine the responsiveness to infliximab treatment.

all patients will have chest x-ray and pregnancy test (if female) prior to infliximab treatment. there will be total 5 study visits. at each visit, body weight will be measured, abdominal exam will be performed , 2 tablespoonful of blood will be drawn, stool will be collected, a questionnaire will be completed.

Eligibility criteria:
inclusion criteria: * newly diagnosed or exacerbating cd (moderate to severe cd). * the diagnosis of moderate to severe cd will be confirmed by previous endoscopy and biopsy. * have the capacity to understand and sign an informed consent form.

Keywords: crohn's infliximab inflammatory bowel disease digestive tract interleukin
biomarker cost-benefit analysis of efnep

Conditions: Chronic Disease

Summary: the goal of this integrated project is to assess whether efnep is a cost-effective nutrition education intervention that generates sustained improvement in chronic disease biomarkers. this project will be unique in its use of objective biomarkers, instead of self-reported behaviors, to quantify the economic benefits generated by efnep through chronic disease prevention. a paired location untreated control group quasi-experimental design will be employed, with biomarkers (bmi, blood pressure, hba1c) measured for 500 adults across four representative state efnep programs (co, fl, md, wa). biomarkers will be measured pre-efnep, 6-months-post-efnep and 1-year-post-efnep. analytical techniques will include cost-benefit, bivariate, and multivariate analyses.

according to the cdc, 60% of us adults have a diagnosed chronic disease. this indicates the need for focused efforts to change modifiable risk factors including diet and exercise. the expanded food and nutrition education program (efnep) aims to prevent chronic diseases by educating and encouraging vulnerable populations to adopt a healthy diet and physical activity. addressing the program priority area diet, nutrition and the prevention of chronic diseases, the long-term goal of this integrated project is to assess whether efnep is a cost-effective nutrition education intervention that generates sustained improvement in chronic disease biomarkers. this project will be unique in its use of objective biomarkers, instead of self-reported behaviors, to quantify the economic benefits generated by efnep through chronic disease prevention. project research objectives include analyzing efnep's sustained impact on chronic disease biomarkers and developing and applying a biomarker-based cost-benefit analysis methodology. extension objectives are to develop an online cost-benefit analysis tool and webinar for nutrition education program evaluation. education objectives are to provide graduate students with experiential learning opportunities in data collection and analysis. a paired location untreated control group quasi-experimental design will be employed, with biomarkers (bmi, blood pressure, hba1c) measured for 500 adults across four representative state efnep programs (co, fl, md, wa). biomarkers will be measured pre-efnep, 6-months-post-efnep and 1-year-post-efnep. analytical techniques will include cost-benefit, bivariate, and multivariate analyses. project results will expand the efnep knowledge-base, allowing for program content and delivery modifications that maximize the impact of taxpayer dollars allocated to chronic disease prevention.

Eligibility criteria:
inclusion criteria: * free-living * speaks and understands english and/or spanish * income at or below 185% of the federal poverty line exclusion criteria: * being pregnant, nursing, and/or less than 9-months postpartum

Keywords: diet nutrition education biomarker cost-benefit analysis efnep
real-life experience of tofacitinib in patients with treatment-resistant rheumatoid arthritis

Conditions: Rheumatoid Arthritis; Treatment Adherence and Compliance

Summary: the investigators aimed to present the efficacy and safety data for patients with ra who received tofacitinib therapy in outpatient clinics.

this retrospective cohort study included 35 patients with rheumatoid arthritis who received tofacitinib therapy in rheumatology outpatient clinic between june 2015 and december 2019. patients who received tofacitinib due to unresponsiveness to ≥2 conventional synthetic disease-modifying anti-rheumatic drugs (csdmards) and/or ≥1 biological disease-modifying anti-rheumatic drugs (bdmards) were retrospectively evaluated. demographic characteristics of the patients, the disease activity score-28 for rheumatoid arthritis with erythrocyte sedimentation rate (das 28-4 (esr)), change in das-28, health assessment questionnaire score, visual analogue scale score, and laboratory parameters such as erythrocyte sedimentation rate (esr), c-reactive protein (crp) level, hemogram, lipid parameters, and uric acid were recorded. the data at six months of treatment were compared with baseline data. the effects related to the treatment as well as the undesired consequences were evaluated.

Eligibility criteria:
inclusion criteria: patients who received tofacitinib due to unresponsiveness to ≥2 csdmards and/or ≥1 bdmards were retrospectively evaluated. - exclusion criteria: patients who could not tolerate the treatment and whose follow-up results could not be reached were excluded from the study. -

Keywords: rheumatoid arthritis tofacitinib disease activity
retrospective study of patients with acute presentation for asthma to an emergency department in uk (rapae)

Conditions: Asthma Acute

Summary: study team will obtain a list of all patients who have been seen in a+e over the past 6 years with a discharge diagnosis of asthma. their history will be reviewed from their a+e notes. team will obtain weight and height from electronic prescribing tool and will obtain compliance information and past medical history from participant's gp records. team will use participant's postcode to word out socio economic status quintile using office of national statistics tool. the following information will be taken from hospital documentation and from gp records.

1. how many previous admissions in past one year (12 months) 2. how many presentations to a+e in previous one year (12 months) 3. diagnosis not confirmed therefore not on any ics 4. poor compliance (less than 75% of ics and/or laba and/or lama and/or leukotriene prescriptions picked up in past year) 5. recent presentation and maintenance therapy not increased (primary care or secondary care issue) 6. is patient overweight bmi 7. is patient on hormonal therapy, ocp, hrt, male hormones 8. social class quintile from post code of address using ons calculator 9. ethnically diverse (see appendix) 10. first eosinophil count on index admission 11. highest eosinophil count in past (ever) and date 12. treatment for diabetes type 2 13. treatment for diabetes type 1 14. treatment for hypertension 15. smoker ever (pack year) when gave up__________ after obtaining this information study team will use simple statistical methods such as frequency and associations with confidence intervals to investigate which factors are associated with frequency of presentation to a+e. they will ascertain the frequency of patients who are on maximum therapy and may benefit from biological therapy, especially if they have raised eosinophils in the past year.

Eligibility criteria:
inclusion criteria: * all asthmatics patients who attend emergency department over 5 years exclusion criteria: * none asthmatics.
study of ocular torsion in patients suffering from palsy of the superior rectus extraocular muscle

Conditions: Superior Rectus Palsy

Summary: retrospective medical chart and medical imaging file review of patients suffering from palsy of the superior rectus extraocular muscle


Eligibility criteria:
inclusion criteria: * patient with unilateral muscular palsy of the superior rectus muscle * patient must have a binocular vision as characterized by lang test exclusion criteria: * bilateral impairment of the superior rectus muscle * presence of an orbital lesion (orbital trauma, tumor or pseudo-tumor) * thyroid orbitopathy * no binovular vision